Format

Send to

Choose Destination
Mol Ther. 2016 Nov;24(11):1974-1986. doi: 10.1038/mt.2016.158. Epub 2016 Aug 10.

Dual Therapeutic Action of a Neutralizing Anti-FGF2 Aptamer in Bone Disease and Bone Cancer Pain.

Author information

1
Ribomic Inc., Tokyo, Japan.
2
Ribomic Inc., Tokyo, Japan; Institute of Medical Science, The University of Tokyo, Tokyo, Japan. Electronic address: nak@ims.u-tokyo.ac.jp.

Abstract

Fibroblast growth factor 2 (FGF2) plays a crucial role in bone remodeling and disease progression. However, the potential of FGF2 antagonists for treatment of patients with bone diseases has not yet been explored. Therefore, we generated a novel RNA aptamer, APT-F2, specific for human FGF2 and characterized its properties in vitro and in vivo. APT-F2 blocked binding of FGF2 to each of its four cellular receptors, inhibited FGF2-induced downstream signaling and cells proliferation, and restored osteoblast differentiation blocked by FGF2. APT-F2P, a PEGylated form of APT-F2, effectively blocked the bone disruption in mouse and rat models of arthritis and osteoporosis. Treatment with APT-F2P also exerted a strong analgesic effect, equivalent to morphine, in a mouse model of bone cancer pain. These findings demonstrated dual therapeutic action of APT-F2P in bone diseases and pain, providing a promising approach to the treatment of bone diseases.

PMID:
27506449
PMCID:
PMC5154475
DOI:
10.1038/mt.2016.158
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center